CMED Resolution No. 3/2025, effective as of April 29, 2026, redefines the pricing criteria applicable to new medicines and new presentations, as well as the deadlines and procedures for submission of the Price Information Document (DIP – Price Information Document).
The new regulation applies to new price submissions, as well as to:
- DIP review proceedings pending a first-instance decision within the CMED Executive Secretariat;
- Products classified as omitted cases and pending a first-instance decision by the Technical-Executive
Committee; and - Products for which CMED has established provisional prices.
